Endomyocardiosclerosis Familial

Endomyocardiosclerosis Familial: Understanding, Diagnosis and Treatment

Introduction

Familial endomyocardiosclerosis, also known as familial endomyocardiosclerosis, is a rare inherited heart disease characterized by sclerosis of the endomyocardium and myocardium. This condition can lead to heart failure and other heart complications. In this article we will consider the main aspects of familial endomyocardiosclerosis, including its description, diagnosis and treatment.

Description

Familial endomyocardiosclerosis is a genetic disease that runs in families. It is characterized by sclerosis of the endomyocardium and myocardium, which leads to thickening of the walls of the heart and a decrease in its elasticity. As a result, the heart muscle cannot contract and relax effectively, resulting in impaired heart function.

Symptoms and diagnosis

Symptoms of familial endomyocardiosclerosis may vary depending on the extent of heart damage. Some common symptoms include shortness of breath, fatigue, swelling and palpitations. Patients may also experience an enlarged heart during exercise and changes in the electrocardiogram.

Diagnosis of familial endomyocardiosclerosis includes various research methods. The doctor may do a physical examination, including auscultation of the heart and evaluation of symptoms. In addition, additional tests such as an electrocardiogram (ECG), echocardiography (ultrasound of the heart), and magnetic resonance imaging (MRI) are performed to evaluate the structure and function of the heart.

Treatment

To date, familial endomyocardiosclerosis has no specific treatment. Treatment is aimed at relieving symptoms and managing complications. Your doctor may prescribe drug therapy to reduce the workload on your heart, control arrhythmias, and improve heart function. In some cases, surgery such as a heart transplant or pacemaker implantation may be required.

In addition, it is important to conduct regular monitoring and control in patients with familial endomyocardiosclerosis. This includes regular visits to your doctor, following lifestyle recommendations (eg, limiting physical activity, eating a healthy diet), and taking prescribed medications.

Forecast and research

The prognosis for patients with familial endomyocardiosclerosis can be varied, depending on the degree of heart damage and the presence of complications. In some cases, the disease can progress and lead to heart failure or cardiac arrhythmias. However, early detection and management of symptoms can help improve patients' prognosis and quality of life.

Research into familial endomyocardiosclerosis continues as scientists and medical professionals strive to better understand the genetic mechanisms of the disease, its diagnosis and treatment. Further research may help develop new treatment approaches and improve the prognosis for patients with this condition.

Conclusion

Familial endomyocardiosclerosis is a rare hereditary heart disease that is characterized by sclerosis of the endomyocardium and myocardium. It can lead to heart failure and other heart complications. Early detection, diagnosis, and symptom management are important aspects of caring for patients with familial endomyocardiosclerosis. A better understanding of the genetic mechanisms of this disease and further research may help improve its diagnosis and treatment in the future.

Endomyocardial sclerosis is the most severe of all common cardiac pathological forms. It is characterized by compaction of the myocardial region and thickening of the thickness of the muscular layer of the heart due to the deposition of a large number of collagen fibers. With the disease, the pumping function of the organ deteriorates; with rapid development, serious disturbances in the functioning of the heart are possible, which leads to the death of the patient.

Endomyocardioscler (exception) is a disease that is caused by the deposition of necrotic masses in the area of ​​the internal muscle of the heart. Due to the increased density, the myocardial structure is replaced by young connective tissue muscle. The syndrome is observed in 27% of patients who suffer from rheumatic endocarditis. About 2% of all registered cases of cardiac lysis are associated specifically with the diagnosis of endomyocardial sclerosis.

Chronic sclerosing heart disease often occurs in patients over 30 years of age, men are 8 times more likely than women, mainly after previous myocarditis or endocardial phlebitis. The development of a pathogenic reaction most often leads to the closure of valves located in the left ventricle or its valves, less often in the left coronary artery.

Most often, the disease develops gradually and manifests itself as persistent cardiac pathologies. The most striking symptoms